NDAORALTABLET
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
AROMASIN (exemestane) by Pfizer is aromatase inhibitors [moa]. Approved for breast cancer, metastatic breast cancer, early breast cancer and 1 more indications. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AROMASIN (exemestane) is an oral aromatase inhibitor small molecule that blocks estrogen production in postmenopausal women with hormone receptor-positive breast cancer. It is indicated across multiple breast cancer stages (early, locally advanced, metastatic) as well as off-label use in ovarian, pancreatic, prostate, and other cancers. The drug works by irreversibly inhibiting the aromatase enzyme, thereby reducing circulating estrogen levels and suppressing tumor growth.
$1MPart D
LOE ApproachingDeclining
Aging product with minimal Part D spending signals a contracting market presence; teams are likely consolidating and refocusing on late-stage pipeline assets.
Mechanism of Action
Aromatase Inhibitors
Pharmacologic Class:
Aromatase Inhibitor
Indications (4)
Worked on AROMASIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.